Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Sean_Ainsworth
|
| gptkbp:collaboratedWith |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:focusesOn |
rare diseases
gene therapy lysosomal storage diseases |
| gptkbp:foundedYear |
2009
|
| gptkbp:founder |
gptkb:Matthew_Scholz
|
| gptkbp:fundedBy |
gptkb:Cystic_Fibrosis_Foundation
venture capital investors |
| gptkbp:headquartersLocation |
gptkb:Seattle,_Washington,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Immusoft
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableAchievement |
developing B cell engineering therapies
|
| gptkbp:technology |
Immune System Programming (ISP)
|
| gptkbp:website |
https://www.immusoft.com/
|
| gptkbp:bfsParent |
gptkb:Matthew_Scholz
|
| gptkbp:bfsLayer |
8
|